Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02654015
Other study ID # GCO 16-0027
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2017
Est. completion date September 7, 2022

Study information

Verified date October 2023
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this multicenter single arm feasibility study is to provide an assessment of enrollment and follow up feasibility for this patient population being treated with the Apollo Minimally Invasive Surgical Treatment (MIES). Patients who do not qualify for the INVEST Feasibility Study will be referred to the INVEST Registry study.


Description:

Objective: The primary objective of this multicenter single arm feasibility study is to provide an assessment of enrollment and follow up feasibility for this patient population being treated with the Apollo or Artemis Minimally Invasive Surgical Treatment (MIES). Patients who do not qualify for the INVEST Feasibility Study will be referred to the INVEST Registry study. Study Design: This study will be a prospective, multi-centered trial that will enroll 50 patients at up to 10 United States (US) centers. Patient Population: Patients with moderate-large volume (20-80 cc) supratentorial intracerebral hemorrhage (ICH) who present within 24 hours of symptom onset. Enrolled patients will receive minimally invasive endoscopic evacuation with the Apollo system or Artemis Device. Indication: The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems. The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system or cerebrum. In the present study, the researchers propose to investigate the feasibility of studying this patient population for eventual implementation of efficacy trials.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 7, 2022
Est. primary completion date September 7, 2022
Accepts healthy volunteers No
Gender All
Age group 22 Years to 84 Years
Eligibility Inclusion Criteria: - Patient age = 22 and = 80, or age < 85 with baseline mRS=0 - Supratentorial ICH of volume = 30 mL < 80 ml (measured using A x B X C/2 method) - CT/MR demonstrates ICH stability (< 5 cc growth) at 6 hours after admission scan - If the initial stability scan shows growth, a second stability scan can be performed q12h until stability is demonstrated or until eligibility for the study has lapsed. - NIHSS = 6 - Presenting GCS 5 - 15 - Historical mRS 0 to 2 - Symptom onset < 24 h prior initial CT - Apollo MIES can be initiated within 72h of ictus/bleed - SBP can be controlled < 160 mmHg and sustained at this level for at least 6 hours Exclusion Criteria: - Imaging - Expanding hemorrhage on stability CT/MR scan - "Spot sign" identified on CTA (May perform a second CTA at 12 hours to demonstrate resolution) - Hemorrhagic lesion such as a vascular malformation (cavernous malformation, AVM etc), aneurysm, neoplasm - Hemorrhagic conversion of an underlying ischemic stroke - Infratentorial hemorrhage - Large associated intra-ventricular hemorrhage requiring treatment for IVH-related mass effect or shift due to trapped ventricle (EVD for ICP management is allowed) - Midbrain extension/involvement - Absolute contraindication to CTA, conventional angiography, and MRA - Coagulation Issues - Absolute requirement for long-term anti-coagulation (e.g., Mechanical valve replacement (bio-prostatic valve is permitted), high risk atrial fibrillation) - Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency - Platelet count < 100 x 103 cells/mm3 or known platelet dysfunction - INR > 1.4, elevated prothrombin time or activated partial thromboplastin time (aPTT), which cannot be corrected or otherwise accounted for (i.e., lupus anti-coagulant) - Patient Factors - Presenting GCS 3 or 4. - High risk condition for ischemic stroke (high risk Afib (e.g., mitral stenosis with Afib), symptomatic carotid stenosis) - Requirement for emergent surgical decompression or uncontrolled ICP after EVD - Unable to obtain consent from patient or appropriate surrogate (for patients without competence) - Pregnancy, breast-feeding, or positive pregnancy test [either serum or urine] (Woman of child-bearing potential must have a negative pregnancy test prior to the study procedure.) - Evidence of active infection [indicated by fever (at or over 100.7 °F) and/or open draining wound] at the time of randomization - Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 180 days. - Based on investigator's judgment, patient does not have the necessary mental capacity to participate or is unwilling or unable to comply with protocol follow up appointment schedule. - Active drug or alcohol use or dependence that, in the opinion of the site investigator would interfere with adherence to study requirements. - Currently participating in another interventional (drug, device, etc) research project.

Study Design


Intervention

Device:
Apollo MIES
Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
Other:
Medical Management
Subjects will receive best medical management for intracranial hemorrhage

Locations

Country Name City State
United States University of Buffalo Buffalo New York
United States Geisinger Medical Center Danville Pennsylvania
United States Prisma Health Greenville South Carolina
United States University of Louisville Louisville Kentucky
United States Icahn School of Medicine at Mount Sinai New York New York
United States University of Washington Seattle Washington
United States George Washington University Washington District of Columbia

Sponsors (3)

Lead Sponsor Collaborator
J. Mocco MOUNT SINAI HOSPITAL, University at Buffalo

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Enrolled Within 730 Days of First Enrollment Number of participants enrolled within 730 days of first enrollment to determine rate of recruitment 730 days
Primary Number of Participants With Available mRS Score Rate of Successful Follow up Obtainment based on number of participants with available mRS score at 180 days 180 days
Secondary Stroke Impact Scale - Mobility For each item, the individual is asked to rate the level of difficulty of the item in the past 2 weeks using the following scale:
1 = could not do it at all
2 = very difficult
3 = somewhat difficult
4 = a little difficult
5 = not difficult at all Stroke Impact Scale full scale from 0-45, with higher score indicating better health outcomes
180 days
Secondary Stroke Impact Scale - ADLs For each item, the individual is asked to rate the level of difficulty of the item in the past 2 weeks using the following scale:
1 = could not do it at all
2 = very difficult
3 = somewhat difficult
4 = a little difficult
5 = not difficult at all
Stroke Impact Scale - ADL's full scale from 0-50, with higher score indicating better health outcomes.
180 days
Secondary EQ-5D-5L EQ-5D is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L health states, defined by the EQ-5D-5L descriptive system, may be converted into a single index value. scored as 1 = no problem to 5 = severe problem
Full scale from 0-25, with higher score indicating better health outcomes.
180 days
Secondary Length of Hospital Stay number of days of hospital stay average of 14 days
Secondary Number of Participants With Modified Rankin Score (mRS) Less Than or Equal to 3 Number of participants with modified Rankin score (mRS) less than or equal to 3 to assess global disability assessed.
The Modified Rankin Scale (mRS) The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
180 days
Secondary Number of Participants Who Meet Both Criteria of Reduction of Hemorrhage Volume Predominantly or Only ICH: Number of participants who meet both criteria of reduction of reduction to < 15 cc total volume AND >60% reduction in hemorrhage volume on immediate post-treatment CT scan. Number of participants who meet both criteria of reduction of Hemorrhage volume as indication of surgical success. 180 days
Secondary Number of Participants With IVH (mGraeb > 0) With an mGraeb Score of Less Than or Equal to 5 Predominantly or Only IVH: number of participants with IVH (mGraeb > 0) with an mGraeb score of less than or equal to 5 on day 7 CT scan. Number of participants with IVH (mGraeb > 0) with an mGraeb score of less than or equal to 5 as indication of surgical success. Day 7
Secondary Number of Participants Who Died Within 90 Days of the Procedure Rate of mortality as Safety Endpoint. Number of participants who died within 90 days of the procedure. 90 days
See also
  Status Clinical Trial Phase
Completed NCT00795119 - A Trial to Determine the Efficacy of Near Infrared Spectroscopy to Detect Intracranial Hemorrhage in Children N/A
Completed NCT04062097 - Registration of Idarucizumab for Patients With IntraCranial Hemorrhage
Completed NCT02146040 - Atrial Fibrillation as a Cause of Stroke and Intracranial Hemorrhage Study (The FibStroke Study)
Completed NCT02661672 - INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage N/A
Terminated NCT01463878 - Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study Phase 4
Withdrawn NCT01042574 - The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Phase 4
Completed NCT05517109 - Hemodynamic in Postreperfusion Period and Functional Recovery in Acute Ischemic Stroke Patients N/A
Completed NCT01620203 - Observational Study in Preterm Infants With Intracranial Hemorrhage
Recruiting NCT06096051 - Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage
Completed NCT01850797 - Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot) N/A
Completed NCT01115660 - Stroke Education Intervention Trial - Pilot N/A
Completed NCT00413946 - Does Erythropoietin Improve Outcome in Very Preterm Infants? Phase 2
Recruiting NCT00505505 - Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy Phase 4
Withdrawn NCT05075486 - Quality Improvement to Reduce Mortality or Severe Intracranial Hemorrhage in Neonatal Extracorporeal Life Support N/A
Recruiting NCT05361070 - Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
Completed NCT04839770 - MIECH: The Minimally Invasive Endoscopic Surgery With the Axonpen System for Spontaneous Intracerebral Hemorrhage N/A
Completed NCT02809651 - Confounding Factors in the Detection of Intracranial Hemorrhage With the Infrascanner N/A
Recruiting NCT04819451 - Application of Magnesium-rich Artificial Cerebrospinal Fluid in Subarachnoid Hemorrhage N/A
Terminated NCT00770718 - Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage Phase 1